Clínica Médica

Revisão sistemática | Uso excessivo de testes na atenção à saúde.

10 Fev, 2022 | 13:45h

Overuse of diagnostic testing in healthcare: a systematic review – BMJ Quality & Safety

---

M-A | Tempo para o benefício na redução de AVC após tratamento da pressão arterial em idosos.

10 Fev, 2022 | 13:40h

Time to benefit for stroke reduction after blood pressure treatment in older adults: A meta-analysis – Journal of the American Geriatrics Society

Comunicado de imprensa: New research finds more intensive blood pressure treatment may prevent strokes in older adults – Wiley

---

Estudo de caso-controle de base populacional | Medicamentos e fatores de risco associados com síndrome de Stevens-Johnson e necrólise epidérmica tóxica.

10 Fev, 2022 | 13:39h

Culprit Medications and Risk Factors Associated with Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case–Control Study – American Journal of Clinical Dermatology

---

Tratamento medicamentoso da insuficiência cardíaca com fração de ejeção reduzida: dicas clínicas baseadas em evidências para melhorar a terapia.

10 Fev, 2022 | 13:38h

Medication management for heart failure with reduced ejection fraction – Canadian Family Physician

---

Revisão | Medicamentos biológicos para migrâneas episódicas e crônicas.

10 Fev, 2022 | 13:37h

Biologics for episodic and chronic migraines – Canadian Family Physician

---

Diretrizes europeias para o tratamento de infecções causadas por bacilos Gram-negativos multirresistentes.

10 Fev, 2022 | 13:20h

European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM –European Society of intensive care Medicine) – Clinical Microbiology and Infection

Conteúdo relacionado: IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

---

Opinião | O desenvolvimento de diretrizes de práticas clínicas “é uma bagunça”.

10 Fev, 2022 | 13:19h

Development of clinical practice guidelines ‘is a mess’ – STAT

---

Diretriz atualizada da IDSA para Covid-19 agora apoia o uso de plasma convalescente em pacientes ambulatoriais com COVID-19 leve a moderada sob alto risco de progressão para doença grave.

10 Fev, 2022 | 13:18h

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 – Infectious Diseases Society of America

Conteúdo relacionado: [Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

 

Comentário no Twitter

Update Alert: Revised recommendation on the use of #convalescentplasma in ambulatory patients w/ COVID-19 at high risk of progression to severe disease w/ no other treatment options.

📄: https://t.co/YRCxtdilXT#COVID19Guidelines @JGPharmD @adarsh_bhimraj @RMKGandhi @ShohamTxID pic.twitter.com/KpXnywH362

— IDSA (@IDSAInfo) February 8, 2022

 

---

[Preprint] Vigilância ativa de miocardite e pericardite decorrentes da vacinação contra COVID-19 com vacinas do tipo mRNA em pessoas de 12-39 anos na Itália.

10 Fev, 2022 | 13:13h

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study -medRxiv

Conteúdos relacionados:

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Comentário no Twitter

The incidence of mRNA vaccine myocarditis or pericarditis in Italy in ~3 million vaccinees age 12-39. Excess cases per 100,000; orange is 2nd dose, blue 1st dose. https://t.co/xvdV4qSdHw
Pfizer:~1/100,000 age 12-39, all 2nd dose
Moderna,: >5/100,000, age 12-39, and some 1st dose pic.twitter.com/Y1jfGrU53v

— Eric Topol (@EricTopol) February 9, 2022

 

---

Apesar de raro, o risco de inflamação cardíaca foi maior em quem recebeu vacina contra Covid da Moderna do que naqueles que receberam a dose da Pfizer.

10 Fev, 2022 | 13:11h

Though rare, Moderna Covid vaccine recipients have higher risk of heart inflammation than Pfizer – CNBC

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

---